Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on X about a paper he authored, published in the Journal of Clinical Oncology:
“For a decade, the SoC for HER2+ eBC has been neoadjuvant TCHP. Yet, multiple signs suggest we may be moving towards a new SoC. A more tailored one. In this JCO editorial to NeoCARHP, I review the seismic shocks that are reshaping algorithms for HER2+ eBC.”
Ankur Mehta, Medical Oncologist at Dana-Farber Cancer Institute, shared this post, adding:
“A must-read! Key takeaways
- Stage III HER2+ still needs intensive regimens, as underrepresented in THP trials
- 6 vs 4 cycles of Taxanes, high pCR but tox high
- Agree with Paolo-combine genomic/ctDNA/radiographic response to adapt escalation in neoadj
- Weekly Nab-pac/Pac seems a better alternative to Docetaxel.”
Title: Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Author: Paolo Tarantino
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Paolo Tarantino.